

Boston Scientific and BARD Seize Opportunities in the U.S. Urological Device Market

VANCOUVER, BRITISH COLUMBIA,
CANADA, December 1, 2021

/EINPresswire.com/ -- iData Research ("iData"), a global consulting and market research firm, has just released a suite of 2022 reports for the U.S. urological device markets. One of the most exciting transitions in the urology space has been in the stone management and benign prostate



As the global COVID-19 pandemic restrictions lift, the urology market will recover and exhibit healthy growth over the forecast period."

*Dr. Kamran Zamanian, Senior
Partner and CEO*

hyperplasia (BPH) treatment device markets. Both of these have propelled movements towards the use of medical lasers to treat patients. Additionally, iData forecasts that the U.S. urology market is projected to recover from COVID-19 headwinds with growth driven by technological advancements, and shifts towards minimally invasive procedures.

According to iData's [U.S. Reports for Urological Devices](#), the number of procedures performed is set to increase. With more patients than ever, urologists have made an effort to

perform procedures more efficiently, leading to a shift in common practices and a push towards minimally invasive procedures. In 2022, the number of urological procedures is expected to increase by nearly 7%. This report includes procedure volumes, unit sales, average selling prices, market drivers and limiters, competitive market share analysis, and more.

iData's analysis includes the urinary incontinence, stone management, BPH treatment device, urological endoscope, prostate cancer treatment device, urodynamic equipment, nephrostomy device, and men's reproductive health device markets. In endoscopy, the need for bronchoscopes to diagnose COVID-19 patients quickly created a need for a device where the risk of infection was negligible. This led to the advent of single-use scopes, and a race has begun to apply this technology to all endoscopes, specifically urological endoscopes.

The U.S. market for urological devices is heavily dominated by Boston Scientific and BARD (BD), followed by Olympus and Teleflex. Coloplast, Cook Medical, and Karl Storz are trailing the leaders by a substantial margin, pushing for a larger share of the U.S. market. There are a multitude of other competitors analyzed within this report which have one or more products offered in this

space.

To accurately estimate market shares, units sold, average selling prices, product segments, and brands, iData Research uses its proprietary market and procedure databases, as well as hospital purchase order data to complement its primary and secondary research initiatives.

Follow the link below to receive a Complimentary Executive Summary of the U.S. Market Report Suite for Urological Devices. Other titles such as European, Asia Pacific and Latin American Urological Device Reports are also available:

<https://idataresearch.com/product/urology-market-united-states/>

For Further Information

More insights like this can be found in the latest reports by iData. Please email us at info@idataresearch.net or register online for a brochure and synopsis.

About iData

iData Research is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, and pharmaceutical industries.

www.idataresearch.com

Emma Matrick
iData Research
+1 604-266-6933

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)



This press release can be viewed online at: <https://www.einpresswire.com/article/557362954>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.